Effects of Prazosin HCl on the Urethral Pressure Profile in Patients with Benign Prostatic Hyperplasia

Nakamura, Koji; Kawashita, Eiso; Osumi, Yasushi; Usui, Tsuguru; Ishibe, Tomoyuki

doi:10.1159/000282027

Cited by 3 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Martorana et al [1984] and Baron et al [1988] were the only studies to produce any significant change in a urodynamic parameter, with a significant reduction in the intraprostatic urethral pres sure. A double-blind study of prazosin 3 mg/day as con trast to placebo and an amino acid preparation (Paraprost) produced a significant improvement in flow rate [Yamaguchi et al, 1988], A number of uncontrolled studies have also been reported [Takita et al, 1983;Shimizu et al, 1985;Nakamura et al, 1986;Kohama et al. 1987;Aoki et al, 1988: Kondo et al.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Twelve-Week Placebo-Controlled Study of Prazosin in the Treatment of Prostatic Obstruction

Chapple

Christmas

Milroy³

1990

Urol Int

View full text Add to dashboard Cite

Fifty-eight normotensive patients with benign prostatic hyperplasia and maximum urinary flow rates of less than 15 ml/s were randomly assigned to receive a 12-week course of treatment with prazosin or placebo in a double-blind parallel group trial. Prazosin was administered orally in doses of 0.5 mg and then 1 mg twice daily for 4 days each and 2 mg twice daily for the remainder of the trial. Patients on treatment with prazosin had an increased urinary flow rate as compared to placebo with a significant reduction in maximum voiding detrusor pressure and maximum detrusor pressure at peak urinary flow. Although a significant effect on frequency was not demonstrated, standard parameters of detrusor instability were reduced. Investigators’ double-blind overall assessment of efficacy significantly favoured the prazosin treatment. Twelve patients were excluded from the final analysis, 8 being withdrawn because of adverse effects, 5 on treatment with prazosin and 3 in the placebo group. Oral prazosin appears to be safe and effective in the long-term treatment of patients with benign prostatic hyperplasia.

show abstract

Section: Discussionmentioning

confidence: 99%

“…1988: Bruck et al, 1989. Five of these studies have demonstrated a signifiant increase in free urinary flow rate with a signifi cant reduction in the urethral pressure profile in two [Shimizu et al, 1985;Nakamura et al, 1986].…”

Section: Discussionmentioning

confidence: 99%

A Twelve-Week Placebo-Controlled Study of Prazosin in the Treatment of Prostatic Obstruction

Chapple

Christmas

Milroy³

1990

Urol Int

View full text Add to dashboard Cite

show abstract

“…Recent studies have shown that prazosin, a selective ai-adrenoceptor blocker, improved urinary symptoms and urodynamic parameters in patients with benign prostatic obstruction without troublesome side effects [16][17][18], The present study, a double-blind, multi-insti tutional trial, attempted to more clearly define the ef fects of prazosin in the treatment of bladder outflow obstruction due to benign prostatic hyperplasia.…”

Section: Introductionmentioning

confidence: 94%

Clinical Evaluation of Effects of Prazosin in Patients with Benign Prostatic Obstruction

Yamaguchi

Shiraiwa²,

Kobayashi³

et al. 1990

Urol Int

View full text Add to dashboard Cite

Prazosin, a selective α₁-adrenoceptor blocker, was compared with Paraprost in a double-blind, multi-institutional study in patients with benign prostatic hyperplasia. The trial encompassed 77 evaluable patients in the prazosin group and 79 in the Paraprost group. Both drugs significantly improved obstructive and irritative symptoms. Residual urine (volume or percentage of total urine) was reduced by both prazosin and Paraprost. Average and maximum flow rates increased significantly in the prazosin group while those were unchanged in the Paraprost group. Side effects occurred in 1 patient treated with prazosin (1.1%) and 3 patients with Paraprost (3.3%). Thus, we confirm the clinical value and minimal side effects of prazosin in the treatment of bladder outflow obstruction resulting from benign prostatic hyperplasia.

show abstract

Urethral Closure Pressure Changes with Age in Men

et al. 1996

View full text Add to dashboard Cite

show abstract

Effects of Prazosin HCl on the Urethral Pressure Profile in Patients with Benign Prostatic Hyperplasia

Cited by 3 publications

References 4 publications

A Twelve-Week Placebo-Controlled Study of Prazosin in the Treatment of Prostatic Obstruction

A Twelve-Week Placebo-Controlled Study of Prazosin in the Treatment of Prostatic Obstruction

Clinical Evaluation of Effects of Prazosin in Patients with Benign Prostatic Obstruction

Urethral Closure Pressure Changes with Age in Men

Contact Info

Product

Resources

About